JP2018521977A5 - - Google Patents

Info

Publication number

JP2018521977A5

JP2018521977A5 JP2017561974A JP2017561974A JP2018521977A5 JP 2018521977 A5 JP2018521977 A5 JP 2018521977A5 JP 2017561974 A JP2017561974 A JP 2017561974A JP 2017561974 A JP2017561974 A JP 2017561974A JP 2018521977 A5 JP2018521977 A5 JP 2018521977A5

Authority

JP

Japan

Prior art keywords

gly

val

pro

seq

leu

Prior art date

2016-05-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 25
• 108090000765 processed proteins & peptides Proteins 0.000 claims 25
• 229920001184 polypeptide Polymers 0.000 claims 24
• 102000004196 processed proteins & peptides Human genes 0.000 claims 24
• 230000002163 immunogen Effects 0.000 claims 21
• 239000008194 pharmaceutical composition Substances 0.000 claims 14
• 125000000539 amino acid group Chemical group 0.000 claims 9
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 8
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 7
• 239000004474 valine Substances 0.000 claims 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 6
• 239000002246 antineoplastic agent Substances 0.000 claims 5
• 229940124597 therapeutic agent Drugs 0.000 claims 5
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
• 235000001014 amino acid Nutrition 0.000 claims 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 239000004471 Glycine Substances 0.000 claims 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
• 235000004279 alanine Nutrition 0.000 claims 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 208000011581 secondary neoplasm Diseases 0.000 claims 2
• 125000006850 spacer group Chemical group 0.000 claims 2
• 210000000130 stem cell Anatomy 0.000 claims 2
• ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 claims 1
• CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 claims 1
• 208000035473 Communicable disease Diseases 0.000 claims 1
• 102000016942 Elastin Human genes 0.000 claims 1
• 108010014258 Elastin Proteins 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical group O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims 1
• 239000004189 Salinomycin Substances 0.000 claims 1
• 108010047495 alanylglycine Proteins 0.000 claims 1
• 229940041181 antineoplastic drug Drugs 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• 210000004027 cell Anatomy 0.000 claims 1
• 210000001072 colon Anatomy 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 229920002549 elastin Polymers 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 210000004072 lung Anatomy 0.000 claims 1
• 230000001394 metastastic effect Effects 0.000 claims 1
• 206010061289 metastatic neoplasm Diseases 0.000 claims 1
• 102000039446 nucleic acids Human genes 0.000 claims 1
• 108020004707 nucleic acids Proteins 0.000 claims 1
• 150000007523 nucleic acids Chemical class 0.000 claims 1
• 210000001672 ovary Anatomy 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
• 229960001548 salinomycin Drugs 0.000 claims 1
• 235000019378 salinomycin Nutrition 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• 229960005486 vaccine Drugs 0.000 claims 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1